by @JTC_PALIdev | Oct 10, 2024 | Press Releases
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) and food effects (FE) and includes...
by @JTC_PALIdev | Oct 8, 2024 | Press Releases
– Live webcast fireside chat on Tuesday, October 15th at 4:30 PM ET Carlsbad, CA, Oct. 08, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on...
by @JTC_PALIdev | Sep 25, 2024 | Press Releases
– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose – Completion of pre- Clinical Trial Application (CTA) meeting with Health Canada – Submission of the CTA for the...
by @JTC_PALIdev | Sep 16, 2024 | Press Releases
– Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and fibrotic diseases – Successful completion of nonclinical safety and toxicity studies and continued execution of...
by @JTC_PALIdev | Sep 5, 2024 | Press Releases
Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% of pediatric colitis patients Company is advancing lead program PALI-2108, an orally administered, locally acting colon-specific PDE4...
